H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s ...

Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the smaller biotech ...

Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...

The Trump administration’s decision to cut nearly $500 million in federal support for the development of mRNA vaccines is ...

Arrowhead Stadium – the home of the four-time NFL Super Bowl champion Chiefs – will play host to the Battle Sports Kansas ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...